The predictive value of admission serum and urine carboxypeptidase-B activation peptide for the severity of acute pancreatitis: a meta-analysis

Figures & data

Figure 1. The details of the literature search and study selection process.

Table 1. Baseline characteristics of studies included in this systematic review and meta-analysis.

	Publication		Sample	Mean age	Male/	Severe/		Test	Sample and cutoff	True	False	False	True
Study	year	Country	size	(years)	female	mild	Etiology	method	value (nmol/L)	positive	positive	negative	negative
Pezzilli	2000	Italy	20	67.4	14/6	9/11	Biliary 18, alcoholic 2	RIA	Serum, 1.14-1.19	8	5	1	6
Appelros	2001	Sweden and UK	60	58.4	29/31	12/48	Biliary 26, alcoholic 14, ERCP 7, hyperlipidemia 3, other 10	RIA	Serum, 5.5; Urine, 100	11/12	5/13	1/0	43/35
Müller	2002	Switzerland	85	60.0	57/28	33/52	Biliary 55, alcoholic 21, other 9	ELISA	Serum, 0.4	30	8	3	44
Sáez	2004	Spain	52	62.9	27/25	17/35	Biliary 31, alcoholic 3, ERCP 3, hyperlipidemia 2, other 13	RIA	Serum, 4.97; Urine, 9.18	13/11	11/11	1/3	22/22
AbuHilal	2007	UK	23	NA	NA	7/16	Biliary 9, alcoholic 10, hyperlipidemia 1, other 3	RIA	Serum, 6.0; Urine, 40	7/7	2/1	0/0	13/14
Regnér	2008	Sweden	140	58.1	65/75	16/124	Biliary 66, alcoholic 31, other 43	ELISA	Serum, 2; Urine, 20	12/10	44/31	4/6	79/92
Hjalmarsson	2009	Sweden	59	61.0	24/35	9/50	Biliary 24, alcoholic 14, other, 4, unknown, 17	ELISA	Serum, 8.0; Urine, 100	5/4	9/5	4/5	41/45

Figure 2. The summary results of PLR and NLR for (A) serum CAPAP and (B) urine CAPAP.

Figure 3. The summary results of DOR for (A) serum CAPAP and (B) urine CAPAP.

Figure 4. The AUC for (A) serum CAPAP, (B) urine CAPAP.

Figure 5. Publication bias for (A) serum CAPAP, (B) urine CAPAP.

Data availability statement

The data that support the findings of this study are publicly available in the published articles which have been cited.